Clinical trials
Clinical Trials:
If you or a loved one have been diagnosed with one of the following dementias, we invite you to consider participating in one of our clinical studies. Information about our ongoing and planned clinical trials are available below. If you have questions about any of the studies you see listed, please consult with your physician.
Actively Recruiting
The Phase 2 SHINE study is currently recruiting individuals (50 to 85 years of age) who have mild-to-moderate Alzheimer’s disease. SHINE will enroll up to 144 participants at sites in the United States and Europe. Participants will be randomized to receive either a standard-of-care treatment or the experimental candidate, CT1812 for six months. More information may be found at shineADstudy.com or on clinicaltrials.gov under trial identifier NCT03507790.
Actively Recruiting
The Phase 2 SHIMMER study is currently recruiting individuals (50 to 85 years of age) who have dementia with Lewy bodies. SHIMMER will enroll up to 120 participants in the United States who will be randomized to receive either a standard-of-care treatment or the experimental candidate, CT1812 for six months. More information may be found at shimmerDLBstudy.com or on clinicaltrials.gov under trial identifier NCT05225415.
Active; Not Yet Recruiting
The Phase 2 START study will recruit up to 540 individuals (50 to 85 years of age) in the United States who have early-stage Alzheimer’s disease. Participants will be randomized to receive either a standard-of-care treatment or the experimental candidate, CT1812. The START study is being conducted in collaboration with the Alzheimer’s Clinical Trials Consortium (ACTC).
Please note: CT1812 is an experimental candidate and has not been approved by the U.S. FDA or other regulatory agency
Additional Resources for Patients and their Families:
Alzheimer's Disease
Dementia with Lewy Bodies
Expanded Access Policy
We are a clinical stage biopharmaceutical company engaged in the development of small-molecule therapeutics targeting age-related degenerative diseases. We currently have several clinical studies planned or underway that are designed to measure safety and efficacy outcomes of our experimental medications for patients with Alzheimer’s disease, dry age-related macular degeneration and dementia with Lewy bodies.
At this time, we do not offer expanded access to any of our therapies in development. Rather, before our drug candidates complete their clinical development and are reviewed and approved by regulatory authorities, they can only be accessed through participation in our clinical trials.